Gilead Sciences

This Cancer Screening Company Has A Better 5-Year Return Than Pfizer, Johnson & Johnson And Gilead

'Further Gains Ahead': Stock Market Update For The Week Ahead

Pfizer, Moderna Vaccines, Gilead Treatment In Focus As Health Firms Report Q3 Earnings

'Further Gains Ahead': Stock Market Update For The Week Ahead

Pfizer, Moderna Vaccines, Gilead Treatment In Focus As Health Firms Report Q3 Earnings

Report: Gilead Sciences And Cancer Treatment Company Immunomedics In $20B Deal

Benzinga's Bulls And Bears Of The Week: GM, Intel, Walmart And More

Report: Gilead Sciences And Cancer Treatment Company Immunomedics In $20B Deal

Benzinga's Bulls And Bears Of The Week: GM, Intel, Walmart And More

Benzinga's Bulls And Bears Of The Week: Amazon, Netflix, Starbucks And More

Barron's Picks And Pans: Cisco, Gilead, Netflix, Wayfair And More

Gilead Sciences Recent News

Barron's Picks And Pans: Berkshire Hathaway, Carvana, Madison Square Garden And More

This weekend's Barron's cover story examines how consumer spending will affect the economic recovery. Other featured articles offer energy stock and bond picks, as well as retail stocks poised to thrive.

Benzinga's Weekly Bulls & Bears: AbbVie, Kinder Morgan, Paypal, Starbucks, Wynn And More

Morgan Stanley Expects Galapagos Shares To Rise 10%

Barron's Picks And Pans: Canadian Stocks, NCR, Gilead And More

Gilead Sciences Price Target Trimmed Following A Sobering Q3

Barron's Picks And Pans: Madison Square Garden, Cigna, Kennedy-Wilson And More

Short Interest Surges In Illumina And Vertex Pharmaceuticals

Short Sellers Dump Amgen And Baxalta

Barron's 500: America's Top Companies

Short Sellers Dump Vertex, Load Up On Baxalta

Big Biotech In The Earnings Spotlight

Barron's: Here Comes $20 Oil

Barron's Picks And Pans: Kinder Morgan, Gilead Sciences And More

Mixed Earnings Expectations For Merck And Pfizer

This Dividend ETF Looks Primed For A Solid 2016

More Wild Short Interest Swings In Biotech Stocks

High Hopes For Apple, Alibaba, Other Earnings This Week

Wild Short Interest Swings For These Three Biotech Stocks

In Volatile Markets, Short Sellers Head For Biotechs

Biogen And Gilead Sciences Catch The Eye Of Short Sellers

What TD Ameritrade Investors Bought And Sold Last Month

Gilead Worth $125 After Earnings: Morgan Stanley

Short Sellers Shy Away From Biotech Stocks